Evidence map›Paper›PMID 39287508›Full record

ArticleACS chemical neuroscience2024

A Multimodal, In Vivo Approach for Assessing Structurally and Phenotypically Related Neuroactive Molecules.

Matthew N McCarroll, Elizabeth Sisko, Jung Ho Gong, Jinfeng Teng, Jack Taylor, Douglas Myers-Turnbull, Drew Young, Grant Burley, Lain X Pierce, Ryan E Hibbs and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew N McCarrollDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States.ORCID 0000-0001-7080-3210
Elizabeth SiskoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States.
Jung Ho GongDepartment of Chemistry, Brown University, Providence, Rhode Island 02912, United States.
Jinfeng TengDepartment of Neurobiology, University of California, San Diego, California 92093, United States.
Jack TaylorInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.
Douglas Myers-TurnbullInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.
Drew YoungInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.
Grant BurleyDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States.
Lain X PierceDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States.
Ryan E HibbsDepartment of Neurobiology, University of California, San Diego, California 92093, United States.
David KokelInstitute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, California 94158, United States.
Jason K SelloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94158, United States.ORCID 0000-0001-6263-7902

Funding

Structure and Function of GABA-A ReceptorsR01DA047325 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Ryan E Hibbs, David W Nauen · 2019 to 2026
$4.4M
Research Training in Chemistry and Chemical BiologyT32GM145460 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason E Gestwicki · 2022 to 2026
$3.1M
Studies of the Antibacterial Activity of and Resistance to Molecules Targeting the ClpP PeptidaseR01AI123400 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SELLO, JASON K · 2017 to 2021
$2.9M
New Technologies for Accelerating the Discovery and Characterization of Neuroactives that Address Substance Use DisordersDP1DA058350 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Matthew N McCarroll · 2023 to 2026
$1.9M
Behavior-based chemical screening for GABAergic and startle modifying drugsR01AA022583 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOKEL, DAVID · 2013 to 2017
$1.6M
NIAAA NIH HHS R01 AA022583NIAID NIH HHS R01 AI123400NIDA NIH HHS DP1 DA058350NIDA NIH HHS R01 DA047325NIGMS NIH HHS T32 GM145460
6 · The paper itself

Abstract

A recently reported behavioral screen in larval zebrafish for phenocopiers of known anesthetics and associated drugs yielded an isoflavone. Related isoflavones have also been reported as GABA

Indexed as

BrainIsoflavonesZebrafishAnimalsBehavior, AnimalHumansNeuronsPatch-Clamp TechniquesPhenotypeReceptors, GABA-AReflex, StartleStructure-Activity RelationshipIsoflavonesReceptors, GABA-AanestheticselectrophysiologyGABAisoflavonesneuropharmacologyparadoxical excitationphenotypic screeningstartle responsestructure activity relationshipTSPOzebrafish

Identifiers

PMID39287508
PMCPMC11587515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.